治疗银屑病新药:白细胞介素17A受体拮抗剂布罗达单抗

发布时间：2018-04-01 12:11

本文选题：受体　切入点：白细胞介素　出处：《中国新药与临床杂志》2017年05期

【摘要】：白细胞介素17(IL-17)家族在银屑病的发病过程中发挥重要作用,IL-17A受体拮抗剂能够抑制IL-17的活性。布罗达单抗为一种人源化免疫球蛋白G抗体,对IL-17A受体具有较高的亲和力,能够抑制IL-17所致的炎症反应,在日本已经被批准用于银屑病的治疗。患者对布罗达单抗具有较好的耐受性,最常见的不良事件主要包括鼻咽炎、腹泻、上呼吸道感染等。
[Abstract]:Interleukin 17 (IL-17) family play an important role in the pathogenesis of psoriasis, IL-17A receptor antagonists can inhibit the activity of IL-17. Broda a humanized monoclonal antibody for immunoglobulin G antibodies with high affinity for IL-17A receptor can inhibit the inflammatory reaction caused by IL-17, has been in Japan approved for the treatment of psoriasis. Patients have good tolerance to Broda mAb, the most common adverse events including nasopharyngitis, diarrhea, upper respiratory tract infection.

【作者单位】：临沂市中心医院药学部;
【分类号】：R986

【相似文献】